romla 25 mg/25 mg/g
rafarm sa - grecia - combinatii (lidocainum+prilocainum) - crema - 25mg/25mg/g - anestezice locale amide
ciprofloxacina claris 2mg/ml
orifarm generics a/s - danemarca - ciprofloxacinum - sol. perf. - 2mg/ml - chinolone antibacteriene fluorochinolone
nacralid 2,5 mg
centrafarm services bv - olanda - naratriptanum - compr. film. - 2,5mg - antimigrenoase agonisti selectivi ai receptorilor 5ht
naratriptan stada hemofarm 2,5 mg
centrafarm services bv - olanda - naratriptanum - compr. film. - 2,5 mg - antimigrenoase agonisti selectivi ai receptorilor 5ht
sifitan 50 micrograme/ml
rafarm sa - grecia - latanoprostum - pic. oft., sol. - 50micrograme/ml - antiglaucomatoase si miotice analogi de prostaglandine
vaccin antirabic rabivit-vbf
belvitunifarm, belorusia - fauna sălbatică
orofar intensiv 8,75 mg/doza
infarmade sl. - spania - flurbiprofenum - spray bucofaringian, sol. - 8,75mg/doza - medicamente pentru zona oro-faringiana medicamente pentru zona oro-faringiana
symbicort 80 micrograme/2,25 micrograme/inhalatie
astrazeneca dunkerque production - franta - combinatii (budesonidum+formoterolum) - susp. de inhalat presurizata - 80micrograme/2,25micrograme - adrenergice inhalante adrenergice si alte med. pt. trat. bolilor obstructive c.r
hemosol b0
gambro dasco s.p.a. sondalo plant - italia - combinatii - sol. pt. hemodializa/hemofiltrare - solutii pentru hemodializa si hemofiltrare solutii pentru hemofiltrare
faslodex
astrazeneca ab - fulvestrant - sânii neoplasme - terapia endocrină, anti-estrogeni - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. În pre - sau femeile în pre-menopauză, tratament combinat cu palbociclib ar trebui să fie combinate cu un hormon luteinizant hormonului de eliberare (lhrh) agonist.